Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Historical Holders from Q3 2018 to Q3 2025

Symbol: CRNX on Nasdaq
Type / Class: Equity / Common Stock
Shares outstanding: 94,179,674
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 107,699,166
Holdings value: $4,485,877,349
% of all portfolios: 0.004%
Number of holders: 223
Number of buys: 122
Number of sells: -108
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
FMR LLC	15%	+46%	$466,033,211	+$144,432,819	13,957,268	+44.9%	FMR LLC	31 Mar 2025
VANGUARD GROUP INC	10%	+2%	$310,914,324	+$7,419,559	9,311,600	+2.4%	The Vanguard Group	31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP	8.9%	+45%	$349,109,925	+$107,235,547	8,381,991	+44.3%	Wellington Management Group LLP	30 Sep 2025
Farallon Capital Partners, L.P.	6%		$164,477,866		5,625,098		Dapice Joshua J.	29 Aug 2025

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	107,699,166	$4,485,877,349	+$149,678,962	$8,496,600	$42,553,805	$41.65	223
2025 Q2	104,559,713	$3,007,383,972	+$75,026,414	$422,772	$1,716,972	$28.76	220
2025 Q1	101,790,412	$3,418,305,905	+$9,856,311	$5,420,064	$1,341,600	$33.54	225
2024 Q4	99,690,161	$5,097,004,672	+$758,098,969	$598,221	$1,334,493	$51.13	245
2024 Q3	84,525,573	$4,321,960,073	+$33,724,194	$2,258,620	$1,190,630	$51.1	233
2024 Q2	82,487,807	$3,694,594,767	+$92,152,096	$8,814,672	$12,003,720	$44.79	232
2024 Q1	80,384,076	$3,762,661,947	+$486,785,470	$26,854,897	$29,555,834	$46.81	201
2023 Q4	70,656,199	$2,513,959,167	+$68,274,571	$10,443,730	$18,164,916	$35.58	180
2023 Q3	68,535,017	$2,038,114,354	+$440,832,585	$14,168,136	$15,681,422	$29.74	171
2023 Q2	54,057,835	$974,084,774	-$11,795,159	$380,222	$19,822	$18.02	138
2023 Q1	55,062,782	$884,310,368	+$2,280,401	$1,606	$362,956	$16.06	127
2022 Q4	54,817,398	$1,003,122,430	-$14,306,281	$20,130	$42,090	$18.3	121
2022 Q3	51,456,378	$1,010,816,996	+$16,147,822		$2,426,000	$19.64	118
2022 Q2	50,645,843	$944,532,132	+$94,595,270		$2,492,000	$18.65	109
2022 Q1	45,482,453	$997,426,956	-$15,117,112			$21.95	114
2021 Q4	44,273,322	$1,256,550,441	+$251,517,738			$28.41	114
2021 Q3	33,632,624	$708,150,662	+$17,177,215			$21.05	91
2021 Q2	32,726,853	$616,933,642	+$42,446,903			$18.85	81
2021 Q1	30,730,499	$465,273,247	+$5,520,857			$15.28	78
2020 Q4	30,426,213	$429,299,885	-$4,592,533			$14.11	84
2020 Q3	30,337,604	$475,397,972	-$19,900,117			$15.67	70
2020 Q2	31,451,376	$546,085,663	+$188,712,886			$17.52	79
2020 Q1	20,679,487	$303,862,789	+$45,411,611			$14.7	55
2019 Q4	17,526,211	$439,727,847	-$5,476,519			$25.09	58
2019 Q3	15,234,699	$229,128,583	-$94,271,503			$15.04	60
2019 Q2	18,931,321	$473,283,223	+$31,131,935			$25	63
2019 Q1	17,737,322	$403,697,060	+$20,738,652			$22.76	62
2018 Q4	16,786,897	$503,433,000	+$19,006,654			$29.99	50
2018 Q3	16,164,902	$463,124,000	+$463,124,002			$28.65	49